Dipeptidyl Peptidase (DPP) IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Patients With Type 2 Diabetes

Trial Profile

Dipeptidyl Peptidase (DPP) IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Patients With Type 2 Diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Diabetic foot ulcer; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 18 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top